GlaxoSmithKline recalls

3 official recalls and safety alerts involving GlaxoSmithKline since 2022-06, from FDA · Drug. Newest first. Check the official notice for exact models and batch codes.

This list only includes recalls Recall Atlas has collected since 2021-10. A product not listed here may still be affected; check with GlaxoSmithKline or the relevant agency.

1. 2024-06-12
2. US
   Drugs & medicalClass III

   GlaxoSmithKline LLC recalls Tivicay PD (dolutegravir) 5mg Tablets for Oral Suspension, 60-count bottles, Each carton contains one bottle of 60 tablets, one 30-mL…

   Labeling: Incorrect Lot and/or Expiration Date: The carton has incorrect expiration of 2026-MAY*, whereas the correct expiration date, which is on the tablet bottle label, is 2025-APR.

   FDA · DrugGlaxoSmithKline LLCNationwide within the United StatesOfficial notice →
3. 2024-01-03
4. US
   Drugs & medicalClass III

   GlaxoSmithKline LLC recalls ANORO ELLIPTA (umeclidinium and vilanterol inhalation powder) 62.5 mcg/25mcg. 1 inhaler contains 30 doses (60 blisters total), Rx Only,…

   Failed Release Testing: Coarse Particle Mass for umeclidinium Out of Specification

   FDA · DrugGlaxoSmithKline LLCDistributed Nationwide in the USA and Puerto Rico.Official notice →
5. 2022-06-01
6. US
   Drugs & medicalClass III

   GlaxoSmithKline LLC recalls Tivicay (dolutegravir) Tablets 50 mg, 30-count Bottle, Rx Only, Manufactured for: ViiV Healthcare RTP, NC 27709, NDC 49702-228-13.

   Labeling: incorrect or missing lot and/or expiration date. An incorrect expiration date was printed on the product labeling with an expiration date of January 2027, whereas the correct expiration date is September 2026.

   FDA · DrugGlaxoSmithKline LLCNationwide in the U.S.Official notice →